Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Abnormal Proliferation02:23

Abnormal Proliferation

4.7K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

8.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
8.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity against the Human Malaria Parasite <i>Plasmodium falciparum</i> via Polypharmacological Inhibition of <i>Pf</i>Ark1 and Hemozoin Formation.

ACS chemical biology·2026
Same author

The pyrrolidinamide antimalarial drug MMV367 rapidly clears blood-stage <i>Plasmodium falciparum</i> in healthy adults with experimental malaria.

Science translational medicine·2026
Same author

Structure-Guided Optimization of Novel Inhibitors of <i>Plasmodium</i> Lysyl-tRNA Synthetase with Multistage Activity against Malaria Parasites.

Journal of medicinal chemistry·2026
Same author

Distinct H3K27 Methylation States Drive Cellular Responses to the Histone Demethylase Inhibitor GSK-J4 in Ovarian Cancer Cells.

Molecular cancer therapeutics·2026
Same author

Optimization of Covalent 6-Cyanoquinazoline KRAS<sup>G12C</sup> Inhibitors for the Treatment of Solid Tumors.

Journal of medicinal chemistry·2026
Same author

Distinct H3K27 methylation states drive cellular responses to the histone demethylase inhibitor GSK-J4 in ovarian cancer cells.

Molecular cancer therapeutics·2026

Related Experiment Video

Updated: Oct 17, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K

Expanding Bromodomain Targeting into Neglected Parasitic Diseases.

Cynthia Tallant1, Paul Bamborough2, Chun-Wa Chung3

  • 1Global Health R&D, GlaxoSmithKline, c/ Severo Ochoa 2, 28760 Tres Cantos, Spain.

ACS Infectious Diseases
|October 6, 2021
PubMed
Summary

Bromodomains in parasitic protozoa are a promising drug target. Further research is essential to develop novel antiparasitic drugs with unique mechanisms of action against infectious diseases.

Keywords:
bromodomaindrug discoveryepigeneticskinetoplastidsplasmodiumtargets

More Related Videos

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
08:48

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

12.0K
In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

13.9K

Related Experiment Videos

Last Updated: Oct 17, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K
Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
08:48

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

12.0K
In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

13.9K

Area of Science:

  • Parasitic protozoa research
  • Drug discovery and development
  • Bromodomain protein family

Background:

  • Bromodomains are epigenetic readers involved in gene regulation.
  • Parasitic protozoa cause significant global health burdens.
  • Targeting bromodomains offers a potential strategy for antiparasitic drug development.

Purpose of the Study:

  • To review current data on bromodomains in parasitic protozoa.
  • To highlight recent advancements in this research area.
  • To assess the potential for drug discovery targeting these proteins.

Main Methods:

  • Literature review of published data.
  • Analysis of recent developments in bromodomain research.
  • Evaluation of target tractability for drug discovery.

Main Results:

  • Bromodomains represent a viable target class in parasitic protozoa.
  • Existing data supports further investigation into their therapeutic potential.
  • Significant progress has been made in understanding their role.

Conclusions:

  • Further research is crucial to validate bromodomains as drug targets.
  • Drug discovery campaigns are needed to identify novel antiparasitic agents.
  • Targeting bromodomains could lead to drugs with differentiated mechanisms of action.